Polyfunctional CD8 + T cells are associated with the vaccination-induced control of a novel recombinant influenza virus expressing an HCV epitope

Antiviral Research

Volumn 94, Issue 2, 2012, Pages 168-178

  Tan, Amabel C L ^a   Eriksson, Emily M Y ^a   Kedzierska, Katherine ^a   Deliyannis, Georgia ^a   Valkenburg, Sophie A ^a   Zeng, Weiguang ^a   Jackson, David C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

CD8 + T cells; Hepatitis C virus; Lipopeptide vaccination; Liver

Indexed keywords

[2,3 BIS(PALMITOYLOXY)PROPYL]CYSTEINE BASED LIPOPEPTIDE; EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; LIPOPEPTIDE; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HELPER CELL; HEPATITIS C VIRUS; IN VIVO STUDY; INFLUENZA VIRUS; INOCULATION; LIVER; LUNG; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST; SPLEEN; VACCINATION; VIRAL CLEARANCE; VIRUS LOAD; VIRUS RECOMBINANT;

ADMINISTRATION, INTRANASAL; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; EPITOPES; FEMALE; GENETIC VECTORS; HEPACIVIRUS; INTERFERON-GAMMA; MICE; MICE, TRANSGENIC; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, SYNTHETIC; VIRAL HEPATITIS VACCINES;

HEPATITIS C VIRUS; MUS; ORTHOMYXOVIRIDAE;

EID: 84860297669     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.03.009     Document Type: Article

References (72)

1. Arribillaga L., de Cerio A.L., Sarobe P., Casares N., Gorraiz M., Vales A., Bruna-Romero O., Borras-Cuesta F., Paranhos-Baccala G., Prieto J., Ruiz J., Lasarte J.J. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. Vaccine 2002, 21:202-210.
2. Badr G., Bedard N., Abdel-Hakeem M.S., Trautmann L., Willems B., Villeneuve J.P., Haddad E.K., Sekaly R.P., Bruneau J., Shoukry N.H. Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J. Virol. 2008, 82:10017-10031.
3. Chen S.H., Oakes J.E., Lausch R.N. Synergistic anti-HSV effect of tumor necrosis factor alpha and interferon gamma in human corneal fibroblasts is associated with interferon beta induction. Antiviral Res. 1993, 22:15-29.
4. Chua B.Y., Eriksson E.M., Brown L.E., Zeng W., Gowans E.J., Torresi J., Jackson D.C. A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine 2008, 26:4866-4875.
5. Chua B.Y., Pejoski D., Turner S.J., Zeng W., Jackson D.C. Soluble proteins induce strong CD8+ T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2. J. Immunol. 2011, 187:1692-1701.
6. Ciuffreda D., Comte D., Cavassini M., Giostra E., Buhler L., Perruchoud M., Heim M.H., Battegay M., Genne D., Mulhaupt B., Malinverni R., Oneta C., Bernasconi E., Monnat M., Cerny A., Chuard C., Borovicka J., Mentha G., Pascual M., Gonvers J.J., Pantaleo G., Dutoit V. Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. Eur. J. Immunol. 2008, 38:2665-2677.
7. Crispe I.N., Dao T., Klugewitz K., Mehal W.Z., Metz D.P. The liver as a site of T-cell apoptosis: graveyard, or killing field?. Immunol. Rev. 2000, 174:47-62.
8. Day E.B., Zeng W., Doherty P.C., Jackson D.C., Kedzierska K., Turner S.J. The context of epitope presentation can influence functional quality of recalled influenza A virus-specific memory CD8+ T cells. J. Immunol. 2007, 179:2187-2194.
9. Deliyannis G., Jackson D.C., Ede N.J., Zeng W., Hourdakis I., Sakabetis E., Brown L.E. Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. J. Virol. 2002, 76:4212-4221.
10. Deliyannis G., Kedzierska K., Lau Y.F., Zeng W., Turner S.J., Jackson D.C., Brown L.E. Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. Eur. J. Immunol. 2006, 36:770-778.
11. Dorner M., Horwitz J.A., Robbins J.B., Barry W.T., Feng Q., Mu K., Jones C.T., Schoggins J.W., Catanese M.T., Burton D.R., Law M., Rice C.M., Ploss A. A genetically humanized mouse model for hepatitis C virus infection. Nature 2011, 474:208-211.
12. Eisenbach C., Neumann-Haefelin C., Freyse A., Korsukewitz T., Hoyler B., Stremmel W., Thimme R., Encke J. Immune responses against HCV-NS3 after accidental infection with HCV-NS3 recombinant vaccinia virus. J. Viral Hepat. 2007, 14:817-819.
13. El-Gogo S., Staib C., Lasarte J.J., Sutter G., Adler H. Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model. J. Gene Med. 2008, 10:177-186.
14. Elmowalid G.A., Qiao M., Jeong S.H., Borg B.B., Baumert T.F., Sapp R.K., Hu Z., Murthy K., Liang T.J. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc. Natl. Acad. Sci. USA 2007, 104:8427-8432.
15. Firat H., Garcia-Pons F., Tourdot S., Pascolo S., Scardino A., Garcia Z., Michel M.L., Jack R.W., Jung G., Kosmatopoulos K., Mateo L., Suhrbier A., Lemonnier F.A., Langlade-Demoyen P. H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur. J. Immunol. 1999, 29:3112-3121.
16. Firat H., Cochet M., Rohrlich P.S., Garcia-Pons F., Darche S., Danos O., Lemonnier F.A., Langlade-Demoyen P. Comparative analysis of the CD8(+) T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice. Int. Immunol. 2002, 14:925-934.
17. Fried M.W., Jensen D.M., Rodriguez-Torres M., Nyberg L.M., Di Bisceglie A.M., Morgan T.R., Pockros P.J., Lin A., Cupelli L., Duff F., Wang K., Nelson D.R. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology 2008, 48:1033-1043.
18. Graham M.B., Braciale T.J. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J. Exp. Med. 1997, 186:2063-2068.
19. Gruener N.H., Lechner F., Jung M.C., Diepolder H., Gerlach T., Lauer G., Walker B., Sullivan J., Phillips R., Pape G.R., Klenerman P. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J. Virol. 2001, 75:5550-5558.
20. Gruner N.H., Gerlach T.J., Jung M.C., Diepolder H.M., Schirren C.A., Schraut W.W., Hoffmann R., Zachoval R., Santantonio T., Cucchiarini M., Cerny A., Pape G.R. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J. Infect. Dis. 2000, 181:1528-1536.
21. Guidotti L.G., Ishikawa T., Hobbs M.V., Matzke B., Schreiber R., Chisari F.V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996, 4:25-36.
22. Heintges T., Wands J.R. Hepatitis C Virus: epidemiology. Hepatology 1997, 521-526.
23. Hikono H., Kohlmeier J.E., Takamura S., Wittmer S.T., Roberts A.D., Woodland D.L. Activation phenotype, rather than central- or effector-memory phenotype, predicts the recall efficacy of memory CD8+ T cells. J. Exp. Med. 2007, 204:1625-1636.
24. Himoudi N., Abraham J.D., Fournillier A., Lone Y.C., Joubert A., Op De Beeck A., Freida D., Lemonnier F., Kieny M.P., Inchauspe G. Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection. J. Virol. 2002, 76:12735-12746.
25. Hoffmann E., Neumann G., Kawaoka Y., Hobom G., Webster R.G. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. USA 2000, 97:6108-6611.
26. Holz L.E., Warren A., Le Couteur D.G., Bowen D.G., Bertolino P. CD8+ T cell tolerance following antigen recognition on hepatocytes. J. Autoimmun. 2010, 34:15-22.
27. Jackson D.C., Lau Y.F., Le T., Suhrbier A., Deliyannis G., Cheers C., Smith C., Zeng W., Brown L.E. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc. Natl. Acad. Sci. USA 2004, 101:15440-15445.
28. Kasprowicz V., Kang Y.H., Lucas M., Schulze zur Wiesch J., Kuntzen T., Fleming V., Nolan B.E., Longworth S., Berical A., Bengsch B., Thimme R., Lewis-Ximenez L., Allen T.M., Kim A.Y., Klenerman P., Lauer G.M. Hepatitis C virus (HCV) sequence variation induces an HCV-specific T-cell phenotype analogous to spontaneous resolution. J. Virol. 2010, 84:1656-1663.
29. Keating R., Yue W., Rutigliano J.A., So J., Olivas E., Thomas P.G., Doherty P.C. Virus-specific CD8+ T cells in the liver: armed and ready to kill. J. Immunol. 2007, 178:2737-2745.
30. Kedzierska K., Turner S.J., Doherty P.C. Conserved T cell receptor usage in primary and recall responses to an immunodominant influenza virus nucleoprotein epitope. Proc. Natl. Acad. Sci. USA 2004, 101:4942-4947.
31. Klade C.S., von Gabain A.M.M. Significant continuous viral load decline in treatment-naive HCV genotype 1patients after therapeutic peptide vaccination with IC41. Hepatology 2009, 50:A1558.
32. La Gruta N.L., Thomas P.G., Webb A.I., Dunstone M.A., Cukalac T., Doherty P.C., Purcell A.W., Rossjohn J., Turner S.J. Epitope-specific TCRbeta repertoire diversity imparts no functional advantage on the CD8+ T cell response to cognate viral peptides. Proc. Natl. Acad. Sci. USA 2008, 105:2034-2039.
33. Lau Y.F., Deliyannis G., Zeng W., Mansell A., Jackson D.C., Brown L.E. Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. Int. Immunol. 2006, 18:1801-1813.
34. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., Robbins G., Phillips R., Klenerman P., Walker B.D. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 2000, 191:1499-1512.
35. Lukens J.R., Dolina J.S., Kim T.S., Tacke R.S., Hahn Y.S. Liver is able to activate naive CD8+ T cells with dysfunctional anti-viral activity in the murine system. PLoS One 2009, 4:e7619.
36. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
37. Messaoudi I., Guevara Patino J.A., Dyall R., LeMaoult J., Nikolich-Zugich J. Direct link between mhc polymorphism, T cell avidity, and diversity in immune defense. Science 2002, 298:1797-1800.
38. Meyer-Olson D., Shoukry N.H., Brady K.W., Kim H., Olson D.P., Hartman K., Shintani A.K., Walker C.M., Kalams S.A. Limited T cell receptor diversity of HCV-specific T cell responses is associated with CTL escape. J. Exp. Med. 2004, 200:307-319.
39. Micallef J.M., Kaldor J.M., Dore G.J. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J. Viral Hepat. 2006, 13:34-41.
40. Mikkelsen M., Holst P.J., Bukh J., Thomsen A.R., Christensen J.P. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain. J. Immunol. 2011, 186:2355-2364.
41. Missale G., Bertoni R., Lamonaca V., Valli A., Massari M., Mori C., Rumi M.G., Houghton M., Fiaccadori F., Ferrari C. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J. Clin. Invest. 1996, 98:706-714.
42. Murata K., Lechmann M., Qiao M., Gunji T., Alter H.J., Liang T.J. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc. Natl. Acad. Sci. USA 2003, 100:6753-6758.
43. Nelson D.R., Marousis C.G., Davis G.L., Rice C.M., Wong J., Houghton M., Lau J.Y. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J. Immunol. 1997, 158:1473-1481.
44. Neuman M.G., Benhamou J.P., Malkiewicz I.M., Akremi R., Shear N.H., Asselah T., Ibrahim A., Boyer N., Martinot-Peignoux M., Jacobson-Brown P., Katz G.G., Le Breton V., Le Guludec G., Suneja A., Marcellin P. Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. Clin. Biochem. 2001, 34:173-182.
45. Neveu B., Debeaupuis E., Echasserieau K., le Moullac-Vaidye B., Gassin M., Jegou L., Decalf J., Albert M., Ferry N., Gournay J., Houssaint E., Bonneville M., Saulquin X. Selection of high-avidity CD8 T cells correlates with control of hepatitis C virus infection. Hepatology 2008, 48:713-722.
46. Nisii C., Tempestilli M., Agrati C., Poccia F., Tocci G., Longo M.A., D'Offizi G., Tersigni R., Lo Iacono O., Antonucci G., Oliva A. Accumulation of dysfunctional effector CD8+ T cells in the liver of patients with chronic HCV infection. J. Hepatol. 2006, 44:475-483.
47. Pascolo S., Bervas N., Ure J.M., Smith A.G., Lemonnier F.A., Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J. Exp. Med. 1997, 185:2043-2051.
48. Pavic I., Polic B., Crnkovic I., Lucin P., Jonjic S., Koszinowski U.H. Participation of endogenous tumour necrosis factor alpha in host resistance to cytomegalovirus infection. J. Gen. Virol. 1993, 74:2215-2223.
49. Penna A., Pilli M., Zerbini A., Orlandini A., Mezzadri S., Sacchelli L., Missale G., Ferrari C. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology 2007, 45:588-601.
50. Phillips S., Chokshi S., Riva A., Evans A., Williams R., Naoumov N.V. CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J. Immunol. 2010, 184:287-295.
51. Polakos N.K., Klein I., Richter M.V., Zaiss D.M., Giannandrea M., Crispe I.N., Topham D.J. Early intrahepatic accumulation of CD8+ T cells provides a source of effectors for nonhepatic immune responses. J. Immunol. 2007, 179:201-210.
52. Price D.A., West S.M., Betts M.R., Ruff L.E., Brenchley J.M., Ambrozak D.R., Edghill-Smith Y., Kuroda M.J., Bogdan D., Kunstman K., Letvin N.L., Franchini G., Wolinsky S.M., Koup R.A., Douek D.C. T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity 2004, 21:793-803.
53. Robertson J.M., Jensen P.E., Evavold B.D. DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323-339 epitope. J. Immunol. 2000, 164:4706-4712.
54. Schmidt J., Neumann-Haefelin C., Altay T., Gostick E., Price D.A., Lohmann V., Blum H.E., Thimme R. Immunodominance of HLA-A2-restricted hepatitis C virus-specific CD8+ T cell responses is linked to naive-precursor frequency. J. Virol. 2011, 85:5232-5236.
55. Sexton A., De Rose R., Reece J.C., Alcantara S., Loh L., Moffat J.M., Laurie K., Hurt A., Doherty P.C., Turner S.J., Kent S.J., Stambas J. Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques. J. Virol. 2009, 83:7619-7628.
56. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 2005, 5:558-567.
57. Smyk-Pearson S., Tester I.A., Lezotte D., Sasaki A.W., Lewinsohn D.M., Rosen H.R. Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design. J. Infect. Dis. 2006, 194:454-463.
58. Tan A.C., La Gruta N.L., Zeng W., Jackson D.C. Precursor Frequency and Competition Dictate the HLA-A2-Restricted CD8+ T Cell Responses to Influenza A Infection and Vaccination in HLA-A2.1 Transgenic Mice. J. Immunol. 2011, 187:1895-1902.
59. Tannock G.A., Paul J.A., Barry R.D. Relative immunogenicity of the cold-adapted influenza virus A/Ann Arbor/6/60 (A/AA/6/60-ca), recombinants of A/AA/6/60-ca, and parental strains with similar surface antigens. Infect. Immun. 1984, 43:457-462.
60. Tester I., Smyk-Pearson S., Wang P., Wertheimer A., Yao E., Lewinsohn D.M., Tavis J.E., Rosen H.R. Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J. Exp. Med. 2005, 201:1725-1731.
61. Thimme R., Oldach D., Chang K.-M., Steiger C., Ray S.C., Chisari F.V. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 2001, 194:1395-1406.
62. Thimme R., Bukh J., Spangenberg H.C., Wieland S., Pemberton J., Steiger C., Govindarajan S., Purcell R.H., Chisari F.V. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl. Acad. Sci. USA 2002, 99:15661-15668.
63. Torresi J., Stock O.M., Fischer A.E., Grollo L., Drummer H., Boo I., Zeng W., Earnest-Silveira L., Jackson D.C. A self-adjuvanting multiepitope immunogen that induces a broadly cross-reactive antibody to hepatitis C virus. Hepatology 2007, 45:911-920.
64. Urbani S., Amadei B., Fisicaro P., Pilli M., Missale G., Bertoletti A., Ferrari C. Heterologous T cell immunity in severe hepatitis C virus infection. J. Exp. Med. 2005, 201:675-680.
65. Vertuani S., Bazzaro M., Gualandi G., Micheletti F., Marastoni M., Fortini C., Canella A., Marino M., Tomatis R., Traniello S., Gavioli R. Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals. Eur. J. Immunol. 2002, 32:144-154.
66. Vitiello A., Marchesini D., Furze J., Sherman L.A., Chesnut R.W. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 1991, 173:1007-1015.
67. Wallace M.E., Keating R., Heath W.R., Carbone F.R. The cytotoxic T-cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant. J. Virol. 1999, 73:7619-7626.
68. Wedemeyer H., Mizukoshi E., Davis A.R., Bennink J.R., Rehermann B. Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. J. Virol. 2001, 75:11392-11400.
69. Wedemeyer H., He X.-S., Nascimbeni M., Davis A.R., Greenberg H.B., Hoofnagle J.H., Liang T.J., Alter H., Rehermann B. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J. Immunol. 2002, 169:3447-3458.
70. Wolfl M., Rutebemberwa A., Mosbruger T., Mao Q., Li H.M., Netski D., Ray S.C., Pardoll D., Sidney J., Sette A., Allen T., Kuntzen T., Kavanagh D.G., Kuball J., Greenberg P.D., Cox A.L. Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire. J. Immunol. 2008, 181:6435-6446.
71. Zeng W., Ghosh S., Lau Y.F., Brown L.E., Jackson D.C. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J. Immunol. 2002, 169:4905-4912.
72. Zeng W., Eriksson E.M., Lew A., Jackson D.C. Lipidation of intact proteins produces highly immunogenic vaccine candidates. Mol. Immunol. 2011, 48:490-496.